Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 373,459,968
  • Shares Outstanding, K 2,682,902
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.68
  • Price/Sales 4.60
  • Price/Cash Flow 12.83
  • Price/Book 6.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 2.42
  • Number of Estimates 7
  • High Estimate 2.50
  • Low Estimate 2.30
  • Prior Year 2.10
  • Growth Rate Est. (year over year) +15.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
134.42 +3.56%
on 04/11/19
140.85 -1.17%
on 04/23/19
+2.29 (+1.67%)
since 03/22/19
3-Month
127.18 +9.45%
on 01/25/19
140.85 -1.17%
on 04/23/19
+12.17 (+9.58%)
since 01/24/19
52-Week
118.62 +17.35%
on 05/29/18
148.99 -6.57%
on 12/04/18
+13.01 (+10.31%)
since 04/24/18

Most Recent Stories

More News
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

JNJ : 139.20 (-0.50%)
ABBV : 78.67 (+0.01%)
RHHBY : 32.7700 (-0.36%)
BIIB : 224.40 (-2.52%)
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional...

ARWR : 18.94 (-0.68%)
JNJ : 139.20 (-0.50%)
Responsible Leaders Summit to Honour Rabbi Arthur Schneier, Johnson & Johnson's Alex Gorsky, Statkraft's Christian Rynning-Tonnesen and Renowned Journalist Ann Curry with Leadership Awards

The Centre for Responsible Leadership will honour Rabbi Arthur Schneier, Johnson & Johnson Chairman of the Board and Chief Executive Officer Alex Gorsky, Statkraft CEO Christian Rynning-Tonnesen and renowned...

JNJ : 139.20 (-0.50%)
Watch for Johnson&Johnson to Potentially Pullback After Gaining 1.86% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $138.69 to a high of $140.40. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of...

JNJ : 139.20 (-0.50%)
SmarTrend Watching for Potential Pullback in Shares of Johnson&Johnson After 1.86% Gain

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $138.69 to a high of $140.40. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of...

JNJ : 139.20 (-0.50%)
Johnson & Johnson Innovation Announces New Research That May Lead to Opportunities for Earlier Interception Strategies in Lung Cancer

Johnson & Johnson Innovation LLC announced today that new data published in Nature Communications reveals the potential role of the immune system in the early development of lung cancer. These findings...

JNJ : 139.20 (-0.50%)
Kraft Heinz CEO stepping down, Patricio named successor

PITTSBURGH (AP) — Kraft Heinz Co. has named a new CEO as it struggles to remain relevant amid changing American tastes.

BUD : 88.21 (-1.17%)
JNJ : 139.20 (-0.50%)
BRK.B : 210.57 (-0.49%)
Aveeno® Haircare Announces Daphne Oz as Brand Ambassador

Today, Aveeno® Haircare announces Daphne Oz, best-selling author and Emmy-winning television host, as its first-ever Brand Ambassador. In 2019, Aveeno Haircare relaunched under Vogue International, a...

JNJ : 139.20 (-0.50%)
Global Lennox-Gastaut Syndrome Treatment Market 2019-2023 - Key Players are Eisai, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson Services, and Supernus Pharmaceuticals - ResearchAndMarkets.com

The "Global Lennox-Gastaut Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

JNJ : 139.20 (-0.50%)
SUPN : 36.96 (-0.86%)
GSK : 39.93 (-0.72%)
Aspen Technology Appoints Georgia Keresty PhD, MPH to Its Board of Directors

Aspen Technology, Inc. (NASDAQ: AZPN), the asset optimization(TM) software company, today announced that Georgia Keresty has been appointed to the Aspen Technology board of directors....

JNJ : 139.20 (-0.50%)
AZPN : 114.51 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 140.68
1st Resistance Point 139.94
Last Price 139.20
1st Support Level 138.66
2nd Support Level 138.12

See More

52-Week High 148.99
Last Price 139.20
Fibonacci 61.8% 137.39
Fibonacci 50% 133.81
Fibonacci 38.2% 130.22
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar